Response to Comments on SGLT2 Inhibitors and Muscle Health
Author Information
Author(s): Wood Nathanael, Witte Klaus K., Bowen T. Scott
Primary Institution: University of Leeds
Conclusion
The study provides important insights into the effects of SGLT2 inhibitors on skeletal muscle pathology in patients with heart failure and reduced ejection fraction.
Supporting Evidence
- The study highlights the need for further research on SGLT2 inhibitors and muscle health.
- Sample collection coincided with the approval of SGLT2 inhibitors, allowing for relevant comparisons.
- Standard practices were followed to minimize bias in the study.
Takeaway
The researchers are saying that SGLT2 inhibitors might help with muscle problems in heart failure patients, but more research is needed to understand how they work.
Methodology
The study involved longitudinal sample collection and comparisons between treated and untreated groups, along with controlled experiments in a mouse model.
Potential Biases
The researchers ensured no bias by keeping samples separate from clinical data until analysis.
Limitations
The study did not have definitive diagnoses for all patients' heart failure causes and lacked comprehensive muscle assessments.
Participant Demographics
Participants included older individuals with heart failure and reduced ejection fraction.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website